查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198706

子宫肌瘤治疗市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Uterine Fibroids Treatment Market- Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

子宫肌瘤治疗市场预计在预测期内（2022 年至 2027 年）以 4.5% 的复合年增长率增长。

冠状病毒大流行给全球带来了重大变化，尤其是在医疗保健系统方面。 由于 COVID-19 大流行，所有择期手术都已取消。 子宫肌瘤患者的风险与严重肢体缺血患者的风险不同，但在某些情况下，他们的生活质量会受到不利影响。 因此，减少病毒交叉传播的选择性治疗或准备医院以帮助受感染患者的机会有限，使妇女感到不适和无效的临时治疗。 结果，为减少病毒交叉感染或准备医院结构以帮助感染患者而进行的选择性治疗受到限制，使妇女感到不舒服或无效的临时治疗。我必须应对这种治疗。

子宫肌瘤的患病率在世界范围内很高，越来越多的患者偏好微创治疗和采用技术先进的技术将推动市场发展。 月经过多、盆腔疼痛、不孕、尿频都是子宫肌瘤的症状。 子宫肌瘤是在子宫内生长的平滑肌细胞的良性肿瘤。 病因不明，但危险因素包括种族、年龄、遗传易感性、绝经前状态、高血压、超重和饮食。 根据《当代妇产科》2022年2月发表的文章《纵观子宫肌瘤现状》，预计到50岁时，超过70%的女性会患上子宫肌瘤。

此外，患者对微创和无创子宫肌瘤手术的偏好预计将推动市场发展。 这些手术越来越受欢迎，因为较小的切口可以减少术后疼痛并加快康復速度。 几家领先的公司正在投资研发，以将新的微创和无创手术设备推向市场。 医生经常推荐的一种非切口手术是 MRgFUS（MR 引导聚焦超声）来治疗肌瘤。 在这种治疗中，超声波束用于加热和去除子宫腔内的特定组织。 作为一种非侵入性治疗，副作用很少，患者可以在几天内恢復正常活动。 与开放手术相比，它痛苦小、效果好、感染风险小、恢復快。

此外，作为对未满足需求的回应，还提到了扩大非妇科医生对子宫肌瘤的认识和教育，以及通过共同决策促进对患者的个体化治疗。 例如，2021 年 11 月，专门从事 AUB 治疗的女性健康公司 Minerva Surgical 宣布推出针对女性的全新消费者教育体验，www.aubandme.com。 此外，研究新型非激素药物疗法可能会带来不影响生殖功能的先进肌瘤治疗方案。 例如，维生素 D 的上调可以保护肌瘤的生长，同时不会对卵巢功能产生不利影响。 此外，Bayer 正在投资子宫肌瘤，作为其临床开发计划的一部分。

因此，先进产品的可用性、手术技术以及各种市场参与者的举措都有助于整个市场的增长。

子宫肌瘤治疗市场趋势

在子宫肌瘤治疗市场，子宫切除领域有望占据主要市场份额

COVID-19 的全球影响仍在继续，因为所有国家/地区的医院都在减少选择性和非紧急病例，以便他们可以将人员和资源分配到其他地方。 根据 2021 年发表的文章“COVID-19 大流行时代的妇科腹腔镜手术”。 一项前瞻性研究”，美国妇产科医师和腹腔镜医师协会 (AAGL)、美国妇产科医师学会 (ACOG) 和其他机构发表联合声明，呼吁结束择期手术，将重点转移到急诊和癌症上手术。我建议。

子宫切除手术数量的增加是市场增长的主要驱动力之一。 此外，这种方法是最流行和最有效的永久性肌瘤治疗方法。 因此，该类别将随着相关手术数量的增加而增长。 根据美国疾病控制与预防中心 (CDC) 的数据，美国每年大约进行 600,000 例子宫切除术，正如 Verywell Health 于 2020 年 11 月发布的“美国的子宫切除术”。 根据美国妇产科学院的数据，大约三分之一的女性将在 60 岁时进行子宫切除术。

如果月经出血严重，切除是一种常见的手术治疗方法。 在这种微创手术中，子宫内膜通过手术切除。 子宫内膜消融不需要切口，可以在医生办公室进行，无需全身麻醉。 此外，子宫内膜切除术后也有可能怀孕。 因此，消融手术带来的好处预计将推动该领域的发展。

北美占据了很大的市场份额，预计在预测期内也会如此。

COVID-19 大流行对妇科手术产生了重大影响。 美国外科医师学会提议推迟 2020 年 3 月进行的所有非必要侵入性手术。 根据 2021 年 12 月的一篇研究论文“大型学术医院系统对 COVID-19 反应和对妇科手术的影响的分析”，2019 年进行了 1,545 例妇科手术，而 2020 年为 1,545 例。为 942 例，表明减少了39.0%。 子宫切除术是2020年最常见的手术，子宫内膜异位症和子宫肌瘤的手术数量下降最多。 在大流行的高峰期，许多患者在寻求妇科手术治疗方面出现了明显的延误。

该地区完善的医疗保健设施、强有力的政府举措以及与子宫切除术相关的手术和医院就诊的增加正在推动北美市场的发展。 此外，Medtronic、Stryker 和 CooperSurgical, Inc. 等主要参与者的存在以及技术改进产品的可用性都有助于该地区的市场增长。 此外，该地区医疗技术的可及性和强大的分销渠道也促进了肌瘤治疗设备在该地区的采用。

各国政府和商业组织正在通过各种举措提高人们对早期发现和治疗子宫肌瘤的认识。 例如，在美国，七月被指定为“肌瘤宣传月”。 近年来，提高对子宫肌瘤认识的努力有所增加。 White Dress Project、HealthyWomen.org、Fibroids Project 和 Center for Innovative GYN Care 都是众所周知的项目。 White Dress Project 旨在通过筹集研究资金和教授女性基本知识来提高人们对子宫肌瘤的认识。 该运动鼓励和支持女性参与并分享她们的故事。 此外，Fibroids Project 是一个在线社区和网站，致力于帮助女性摆脱肌瘤的困扰。 它旨在让女性和医疗保健专业人员了解当前的研究、举措和治疗。 女性对子宫肌瘤治疗和活动意识的提高预计将推动市场增长。

子宫肌瘤治疗市场竞争者分析

肌瘤治疗市场分散且竞争激烈，由几家主要参与者组成。 市场上的一些参与者是 Myovant Sciences GmbH；Gynesonics、Boston Scientific Corporation、INSIGHTEC、Hologic, Inc、Karl Storz Gmbh、Minerva Surgical, Inc、Pfizer, Inc、Abbvie, Inc 和 ObsEva。 市场参与者正在采取各种战略，如合併、收购和新产品开发，以保持竞争力。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 技术进步
    • 子宫肌瘤患病率增加
  • 市场製约因素
    • 与粉碎器相关的并发症
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分

  • 按类型
    • 浆膜下纤维瘤
    • 硬膜内纤维瘤
    • 黏膜下纤维瘤
    • 闭塞性纤维瘤
  • 按治疗方法
    • 药物治疗
      • 黄体酮製剂
      • 左炔诺孕酮
      • 其他
    • 手术方法
      • 子宫切除术
      • 子宫肌瘤摘除术
      • 肌溶解
      • 其他
  • 最终用户
    • 医院
    • 门诊手术中心
    • 其他
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Myovant Sciences GmbH
    • Gynesonics
    • Medtronic
    • Boston Scientific Corporation
    • INSIGHTEC
    • Hologic, Inc.
    • Karl Storz Gmbh
    • Minerva Surgical, Inc.
    • Pfizer, Inc.
    • Abbvie, Inc.
    • ObsEva

第七章市场机会与未来趋势

简介目录
Product Code: 90589

The Uterine Fibroids Treatment Market is projected to register a CAGR of 4.5% during the forecast period (2022-2027).

The coronavirus pandemic has caused major changes worldwide, especially in healthcare systems. The COVID-19 pandemic resulted in the cancellation of all elective procedures. While patients with uterine fibroids are not at risk in the same way as Critical Limb Ischemia patients are, their quality of life has been adversely impaired in some cases. As a result, restrictions on access to elective therapies, imposed either to decrease virus cross-transmission or to prepare the hospital structure to aid infected patients, have forced women to live with discomfort and ineffective temporary treatments. As a result, restrictions on access to elective therapies, imposed either to decrease virus cross-transmission or to prepare the hospital structure to aid infected patients, have forced women to live with discomfort and ineffective temporary treatments.

The market is likely to be driven by the high prevalence of uterine fibroids among women worldwide, increased patient preference for less invasive procedures, and the adoption of technologically sophisticated technologies. Excessive menstrual flow, pelvic pain, infertility, and frequent urination are all symptoms of uterine fibroid (UF), a benign tumor of the smooth muscle cells that grow in the uterus. Even though the etiology is unknown, race, age, genetic susceptibility, premenopausal status, hypertension, overweight, and diet are all risk factors. Per the article published by Contemporary OB/GYN in February 2022 on "A Look At the Current State of Uterine Fibroid Care," over 70% of women are estimated to develop uterine fibroids by age 50.

Furthermore, the market is predicted to develop due to patients' preference for minimally invasive and non-invasive fibroids operations. Smaller incisions reduce post-operative pain and speed recovery, resulting in the widespread use of these procedures. Several major firms are investing in R&D to bring new minimally invasive and non-invasive surgical devices to market. One of the incision-less techniques physicians commonly suggest is MR-guided Focused Ultrasound (MRgFUS) for treating uterine fibroids. The gadget emits ultrasonic beams, which heat and remove specific tissue from the uterine cavity during this treatment. As this is a non-invasive procedure, there are little to no side effects, and patients can resume normal activities within a few days. As a result of the increased demand for such operations due to their little pain, efficacy, low risk of infection, and quick recovery compared to open surgeries, the market for uterine fibroids treatment devices is expected to rise.

Expanding uterine fibroids awareness and education beyond gynecologic professionals and promoting individualized patient treatment through collaborative decision-making were also flagged as ways to address unmet needs. For example, in November 2021, Minerva Surgical, Inc. (a women's health company specializing in treating AUB) announced the introduction of www.aubandme.com, a new consumer education experience for women. Furthermore, investigating novel non-hormonal medical therapy could lead to advanced fibroids treatment options that do not affect fertility. Upregulation of vitamin D, for example, could protect against fibroid growth while having no harmful influence on ovarian function. Furthermore, Bayer invests in uterine fibroids as part of its clinical development program.

Hence, the availability of advanced products, surgical techniques, and initiatives by various market players contribute to the overall market growth.

Uterine Fibroids Treatment Market Trends

The Hysterectomy Segment is Expected to Hold a Major Market Share in the Uterine Fibroids Treatment Market

The worldwide impact of COVID-19 continues to be felt as hospitals in all countries reduce elective and non-urgent cases to allow staffing and resources to be deployed elsewhere. As per the article published in 2021 on "Gynecological Laparoscopic Surgeries in the Era of COVID-19 Pandemic: A Prospective Study", A joint statement issued by the American Association of Gynecologic Laparoscopists (AAGL), American College of Obstetricians & Gynaecologists (ACOG), and other organizations advised the suspension of elective surgery, shifting the focus to emergency and cancer surgery.

The rising number of hysterectomy surgical procedures is one of the main drivers of market growth. Furthermore, this method is the most popular and well-proven permanent treatment for uterine fibroids. As a result, the category will likely grow as the number of related surgeries increases. As per the article published in November 2020 on "Hysterectomy in the United States", by Verywell Health, according to the Centers for Disease Control and Prevention (CDC), about 600,000 hysterectomies are performed in the United States each year. According to the American College of Obstetricians and Gynecologists, around a third of all women will have a hysterectomy by age 60.

For severe menstrual bleeding, ablation procedures are a frequent surgical treatment. The endometrial lining of the uterus is surgically abated in this minimally invasive procedure. Endometrial ablation requires no incisions and can be performed in the doctor's office without general anesthesia. Furthermore, after the endometrial ablation operation, pregnancy is conceivable. As a result, the advantages afforded by ablation procedures are projected to propel the segment forward.

North America is Expected to Hold a significant share in the market and is expected to do the Same in the Forecast Period.

The pandemic of COVID-19 has a significant impact on gynecologic surgery. The American College of Surgeons suggested delaying all non-essential invasive surgeries in March 2020. According to a December 2021 study article titled "Analysis of COVID-19 Response and Impact on Gynecologic Surgery at a Large Academic Hospital System," 1,545 gynecologic cases were done in 2019, compared to 942 cases in 2020, suggesting a 39.0% decline. The most common procedure in 2020 was a hysterectomy, whereas surgery for endometriosis and uterine fibroids saw the greatest decline in volume. Many patients had significant delays in receiving gynecologic surgical care during the peak pandemic.

The presence of well-established healthcare facilities in the region increased government initiatives, and an increase in hysterectomy-related surgical procedures/hospital visits are all driving the market in North America. Furthermore, the presence of major important companies like Medtronic, Stryker, and CooperSurgical, Inc. and the availability of technologically improved goods all contribute to the region's market growth. Furthermore, the region's adoption of uterine fibroids treatment devices is fueled by the region's easy access to healthcare technologies and strong distribution channels.

Various governments and commercial groups are working to raise awareness of early fibroids detection and treatment through various efforts. In the United States, for example, July is designated as "Fibroids Awareness Month." In recent years, more initiatives have raised awareness about uterine fibroids. The White Dress Project, HealthyWomen.org, Fibroids Project, and Center for Innovative GYN Care are just a few famous programs. The White Dress Project aims to raise awareness about fibroids by generating funding for research and educating women on the basics. This initiative encourages and supports women to join and share their stories. In addition, the Fibroids Project is an online community and website dedicated to assisting women in becoming fibroids-free. They aim to provide information about current research, initiatives, and procedures to both women and medical professionals. Growing awareness among women about uterine fibroids treatment and activities is expected to promote market growth.

Uterine Fibroids Treatment Market Competitor Analysis

The uterine fibroids treatment market is fragmented and competitive and consists of several major players. Some players operating in the market are Myovant Sciences GmbH; Gynesonics, Boston Scientific Corporation, INSIGHTEC, Hologic, Inc., Karl Storz Gmbh, Minerva Surgical, Inc., Pfizer, Inc., Abbvie, Inc., and ObsEva. Market players are adopting various strategies such as mergers, acquisitions, and new product developments to remain competitive.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements
    • 4.2.2 Growing Prevalence of Uterine Fibroids
  • 4.3 Market Restraints
    • 4.3.1 Complications Associated with Morcellators
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Subserosal Fibroids
    • 5.1.2 Intramural Fibroids
    • 5.1.3 Submucosal Fibroids
    • 5.1.4 Pedunculated Fibroids
  • 5.2 By Treatment
    • 5.2.1 Drugs
      • 5.2.1.1 Progesterone
      • 5.2.1.2 Levonorgestrel
      • 5.2.1.3 Others
    • 5.2.2 Surgical Techniques
      • 5.2.2.1 Hysterectomy
      • 5.2.2.2 Myomectomy
      • 5.2.2.3 Myolysis
      • 5.2.2.4 Others
  • 5.3 By End-user
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Myovant Sciences GmbH
    • 6.1.2 Gynesonics
    • 6.1.3 Medtronic
    • 6.1.4 Boston Scientific Corporation
    • 6.1.5 INSIGHTEC
    • 6.1.6 Hologic, Inc.
    • 6.1.7 Karl Storz Gmbh
    • 6.1.8 Minerva Surgical, Inc.
    • 6.1.9 Pfizer, Inc.
    • 6.1.10 Abbvie, Inc.
    • 6.1.11 ObsEva

7 MARKET OPPORTUNITIES AND FUTURE TRENDS